Comparative antihypertensive efficacy of combinations of azilsartan medoxomil or olmesartan medoxomil with amlodipine in patients with arterial hypertension, type 2 diabetes mellitus and non-alcoholic fatty liver disease

Abstract

Оbjective : to compare the effectiveness of the effect of two combination therapy options on office blood pressure (BP), 24-hour blood pressure monitoring (ABPM) and 24-hour BP profile (DAP) in patients with arterial hypertension (AH) associated with type 2 diabetes mellitus (T2D) and non-alcoholic fatty liver disease (NAFLD). Materials and methods: 137 patients with uncontrolled hypertension combined with DM2 and NAFLD were examined. After randomization by the "envelope" method, patients of the 1st group were assigned a combination of azilsartan medoxomil (Az-M) with amlodipine (Aml), the 2nd group a combination of olmesartan medoxomil (Ol-M) with Aml. At baseline, at 4, 8, 12, and 24 weeks, office BP was measured, and ABPM and DAP were analyzed at baseline and at 24 weeks of the study. Results : after 12 weeks in the 1st and 2nd groups, 86,8% and 84,1% of patients, respectively, reached the target level (TA) of blood pressure, which was maintained until the end of the study. After 24 weeks, both groups showed a statistically significant improvement in ABPM parameters and optimization of DAP. At the same time, taking the Ol-M/Aml combination was accompanied by more pronounced positive dynamics of some prognostically important ABPM indicators. Conclusion : despite the significant antihypertensive effect on the background of the use of both combinations, the effect on individual parameters of ABPM Ol-M/Aml was more pronounced.